{"id":63118,"date":"2026-05-14T13:42:30","date_gmt":"2026-05-14T12:42:30","guid":{"rendered":"https:\/\/www.promedical.co.uk\/?p=63118"},"modified":"2026-05-14T13:42:30","modified_gmt":"2026-05-14T12:42:30","slug":"what-the-march-board-says-about-nhs-delivery-in-2026","status":"publish","type":"post","link":"https:\/\/www.promedical.co.uk\/healthcare-leadership\/what-the-march-board-says-about-nhs-delivery-in-2026\/","title":{"rendered":"What the March Board Says About NHS Delivery in 2026"},"content":{"rendered":"

The March 2026 NHS England Board papers describe a system moving from broad recovery planning into a more demanding phase of delivery control.<\/span>\u00a0<\/span><\/p>\n

The overall signal is not one of simple improvement or deterioration. It is more complex. Elective waiting lists are reducing, some urgent and emergency care measures are improving, cancer early diagnosis is moving in the right direction, and parts of mental health access are expanding. At the same time, diagnostic waits, cancer standards, community long waits, workforce engagement, financial\u00a0variation\u00a0and quality assurance indicators all show continuing pressure.\u00a0<\/span>\u00a0<\/span><\/p>\n

For NHS leaders, the significance of the March Board is that these pressures are no longer separate issues. Access recovery, productivity, workforce resilience, financial discipline, patient safety, digital\u00a0transformation\u00a0and NHS England\u2019s own organisational change are now converging. The system is being asked to improve performance while simultaneously\u00a0operating\u00a0under tighter money, thinner management\u00a0bandwidth\u00a0and greater transparency.<\/span>\u00a0<\/span><\/p>\n

That is the central message of the March Board:\u00a0<\/span>2026 is becoming a grip-and-transition year for NHS delivery.<\/span><\/b><\/p>\n

Recovery is visible, but not yet secure<\/h3>\n

The Integrated Performance Report shows important signs of access recovery. The total elective waiting list stood at\u00a0<\/span>7.25 million in January 2026<\/span><\/b>, down from December 2025 and down\u00a0<\/span>180,455<\/span><\/b>\u00a0compared with January 2025. The number of under-18s on the elective waiting list also fell year on year, while the proportion of patients waiting over 52 weeks for elective treatment continued to reduce.\u00a0<\/span>\u00a0<\/span><\/p>\n

This matters because it shows that national recovery efforts are having an effect. Validation, regional oversight, elective tiering,\u00a0additional\u00a0activity\u00a0and Getting It Right\u00a0First Time\u00a0support\u00a0are\u00a0all part of the national delivery approach. But the same report also shows why recovery cannot yet be treated as secure. Referral to Treatment performance at 18 weeks was\u00a0<\/span>61.5%<\/span><\/b>\u00a0in January 2026, still below the 2025\/26 requirement of 65%.\u00a0<\/span>\u00a0<\/span><\/p>\n

The deeper issue is that elective recovery depends on more than theatre lists. It depends on diagnostics, outpatient flow, workforce availability, digital infrastructure, clinical\u00a0prioritisation, estates, discharge, and the capacity of providers to convert activity into sustained pathway improvement.<\/span>\u00a0<\/span><\/p>\n

The diagnostic position is particularly important. In January 2026,\u00a0<\/span>24.7%<\/span><\/b>\u00a0of patients were waiting over six weeks for a diagnostic test, worse than the previous year. Cancer performance also remained below ambition, with the Faster Diagnosis Standard at\u00a0<\/span>72.8%<\/span><\/b>\u00a0and the 62-day standard at\u00a0<\/span>68.4%<\/span><\/b>\u00a0in January 2026.\u00a0<\/span>\u00a0<\/span><\/p>\n

The signal for leaders is clear: elective recovery is real, but it\u00a0remains\u00a0exposed to bottlenecks across the pathway. The next phase of recovery will require targeted,\u00a0governed\u00a0and productive capacity, not simply more activity.<\/span><\/p>\n

Financial balance is becoming financial grip<\/h3>\n

The Month 10 finance paper shows the NHS broadly in balance at national level, with a\u00a0<\/span>\u00a371 million revenue overspend<\/span><\/b>, equivalent to\u00a0<\/span>0.04%<\/span><\/b>\u00a0of year-to-date allocation. On its own, that appears controlled. But beneath the national position, the paper shows system-level financial strain. Systems were overspending by\u00a0<\/span>\u00a3428 million<\/span><\/b>\u00a0year to date, with provider expenditure materially above plan and\u00a0<\/span>14 systems<\/span><\/b>\u00a0formally forecasting a year-end overspend.\u00a0<\/span>\u00a0<\/span><\/p>\n

This distinction matters. The national headline is balance; the local reality is uneven delivery. The paper attributes\u00a0overspends\u00a0largely to\u00a0slippage against efficiency plans, workforce costs above planned levels and the impact of industrial action cover. It also\u00a0states\u00a0that systems forecasting overspends are being required to complete assurance statements and confirm recovery actions, with potential consequences for 2026\/27 planning limits where agreed financial plans are not delivered.\u00a0<\/span>\u00a0<\/span><\/p>\n

This is not only a finance signal. It is a behavioural signal. NHS England is moving from reporting financial pressure to using financial oversight to shape system behaviour. The direction of travel is towards tighter accountability for run-rate improvement, recurrent savings, workforce cost\u00a0control\u00a0and productivity.<\/span>\u00a0<\/span><\/p>\n

That direction is reinforced by the Strategy Committee, which reviewed a Productivity Plan aimed at achieving\u00a0<\/span>2% annual productivity growth<\/span><\/b>. The Committee\u00a0identified\u00a0reducing unwarranted variation as the core route to baseline productivity gains, alongside expanded day-case surgery, scaled diagnostic models and artificial intelligence.\u00a0<\/span>\u00a0<\/span><\/p>\n

For provider and system leaders, this means operational decisions in 2026\/27 will increasingly be judged through a combined lens: access, cost,\u00a0quality\u00a0and productivity. Capacity that does not improve flow, reduce\u00a0variation\u00a0or protect safety will be harder to justify.<\/span><\/p>\n

Workforce resilience is becoming the delivery risk<\/h3>\n

The workforce signal in the March Board pack is one of sustained pressure.<\/span>\u00a0<\/span><\/p>\n

The Integrated Performance Report shows that staff engagement has fallen since 2020. The 2025 NHS Staff Survey engagement score was\u00a0<\/span>6.75<\/span><\/b>, down from\u00a0<\/span>6.85<\/span><\/b>\u00a0in 2024. The National Quarterly Pulse Survey engagement score was reported at\u00a0<\/span>6.46<\/span><\/b>\u00a0in Q4 2025\/26, the lowest\u00a0level since the survey was introduced. Sickness absence also remained slightly higher than the previous year.\u00a0<\/span>\u00a0<\/span><\/p>\n

This is more than a staff experience issue. The report explicitly links engagement to productivity,\u00a0stating\u00a0that a 1% increase in engagement\u00a0generally equates\u00a0to a 1\u20131.5% increase in productivity. Workforce experience therefore sits directly inside the system\u2019s delivery model.\u00a0<\/span>\u00a0<\/span><\/p>\n

The People Committee papers add another layer. The Voluntary Redundancy Programme and wider NHS England Transformation Programme are creating organisational change at the centre while providers and integrated care boards are being asked to deliver recovery. The Committee noted the importance of\u00a0maintaining\u00a0oversight of workforce capability and organisational capacity, with particular attention to specialist capability and key organisational knowledge.\u00a0<\/span>\u00a0<\/span><\/p>\n

The Data, Digital and Technology Committee sharpened this concern. It warned that the Voluntary Redundancy Programme\u00a0represented\u00a0a material and currently unmitigated risk, with scarce specialist capacity being drawn away from critical cyber and resilience work.\u00a0<\/span>\u00a0<\/span><\/p>\n

The signal is that workforce resilience is no longer only about vacancies or rota gaps. It is about the system\u2019s ability to\u00a0retain\u00a0knowledge, sustain morale, protect specialist capacity, support\u00a0managers\u00a0and\u00a0maintain\u00a0delivery focus during structural change.<\/span><\/p>\n

Quality,safetyand variation are moving up the agenda<\/h3>\n

The March Board papers also show that quality and safety are becoming more data-led and more visible.<\/span>\u00a0<\/span><\/p>\n

The Integrated Performance Report records\u00a0<\/span>11 providers<\/span><\/b>\u00a0with higher-than-expected mortality for the period November 2024 to October 2025. It also shows that around two thirds of trusts receiving a CQC safe inspection rating in the previous two years were rated either requires improvement or inadequate.\u00a0<\/span>\u00a0<\/span><\/p>\n

The staff\u00a0raising-concerns\u00a0score also fell to\u00a0<\/span>6.37<\/span><\/b>\u00a0in 2025, down from\u00a0<\/span>6.45<\/span><\/b>\u00a0in 2024. That matters because confidence to raise concerns is a core safety signal. Where staff are less confident that concerns about unsafe clinical practice can be raised or acted upon, the risk is not only cultural. It can become operational, clinical and\u00a0medico-legal.\u00a0<\/span>\u00a0<\/span><\/p>\n

There are positive signals too. Stillbirth and neonatal death rates have reduced, crisis care face-to-face contact within 24 hours has improved, restrictive intervention use in mental health has reduced year on year, and some infection indicators have improved compared with the previous year.\u00a0<\/span>\u00a0<\/span><\/p>\n

But the overall quality signal is variation. Some indicators are moving in the right direction, while others\u00a0remain\u00a0unstable. The system response is also becoming clearer: a new Quality Strategy, more transparency, provider league tables, stronger board accountability, patient-reported\u00a0measures\u00a0and a more data-led regulatory model are all referenced in the Board material.\u00a0<\/span>\u00a0<\/span><\/p>\n

For leaders, the implication is that quality can no longer be treated as separate from access or productivity. Delayed diagnosis, long waits, poor handovers, discharge delays, staff silence, infection control\u00a0variation\u00a0and mortality signals all sit within the same delivery risk environment.<\/span><\/p>\n

The centre is changing while delivery expectations rise<\/h3>\n

The March papers also point to a structural tension: NHS England is redesigning itself while expecting the wider system to deliver more disciplined performance.<\/span>\u00a0<\/span><\/p>\n

The Strategy Committee\u2019s forward pipeline is\u00a0substantial. It includes the 10 Year Health Plan roadmap, urgent and emergency care strategy, elective care strategy, mental health supply-side review, children and young people\u2019s strategy, specialised services review, the 10 Year Workforce Plan, nursing and midwifery strategy, payment reform, market management, commercial strategy, dental reform, Better Care Fund reform and General Medical Services contract reform.\u00a0<\/span>\u00a0<\/span><\/p>\n

The scale of this pipeline matters. It shows that 2026\/27 will not simply be a year of performance management. It will also be a year of policy design, payment reform, workforce redesign, service\u00a0transformation\u00a0and digital dependency.<\/span>\u00a0<\/span><\/p>\n

The Data, Digital and Technology Committee papers show the same tension. The Committee supported the direction of digital change, but raised concerns about business ownership, deliverability, programme coherence, the Single Patient Record\u00a0timeline\u00a0and the need for clearer neighbourhood technology requirements.\u00a0<\/span>\u00a0<\/span><\/p>\n

This creates a difficult leadership environment. Providers and ICBs should expect stronger national data oversight, more transparent performance\u00a0comparison\u00a0and tighter financial accountability. At the same time, NHS England\u2019s own capacity, specialist\u00a0expertise\u00a0and leadership bandwidth are being affected by organisational change.<\/span>\u00a0<\/span><\/p>\n

That combination raises the premium on clarity. Leaders will need to distinguish between what is strategically important, what is operationally deliverable, and what must be deferred until capability and resource are aligned.<\/span>\u00a0<\/span><\/p>\n

What this means now<\/h3>\n

The March Board does not point to a single dominant challenge. It points to a connected delivery test.<\/span>\u00a0<\/span><\/p>\n

The NHS is improving in\u00a0important areas, but the improvement\u00a0remains\u00a0fragile. Elective care is recovering, but diagnostics and cancer standards\u00a0remain\u00a0under pressure. Finance is nationally controlled, but locally strained. Workforce resilience is weakening at the same time as productivity expectations are rising. Quality and safety signals are becoming more transparent. NHS England is restructuring while also asking the system to deliver a major programme of reform.<\/span>\u00a0<\/span><\/p>\n

For provider and system leaders, the practical implication is that 2026\/27 will reward disciplined execution. The system will need targeted capacity,\u00a0not unfocused\u00a0activity. It will\u00a0need workforce models that support resilience, not simply fill gaps. It will need quality assurance that\u00a0identifies\u00a0risk earlier, not only after harm has occurred. And it will need digital and productivity programmes that are connected to operational ownership, not just strategic ambition.<\/span>\u00a0<\/span><\/p>\n

For\u00a0ProMedical\u2019s\u00a0core audience, the March Board should be read as a whole-system signal: the next phase of NHS delivery will be defined by the ability to align access recovery, workforce sustainability, financial\u00a0control\u00a0and clinical safety under one operating model.<\/span>\u00a0<\/span><\/p>\n

The organisations that succeed will be those that can protect patient care while making delivery more productive, more\u00a0transparent\u00a0and more resilient.<\/span>\u00a0<\/span><\/p>\n

References<\/h3>\n

NHS England,\u00a0<\/span>Meeting of the Board of NHS England \u2013 agenda<\/span><\/i>, 26 March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Integrated Performance Report<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Month 10 financial position 2025\/26<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Board Committee updates \u2013 NHS England Strategy Committee<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Board Committee updates \u2013 NHS England People Committee<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Board Committee updates \u2013 Data, Digital and Technology Committee<\/span><\/i>, March 2026.\u00a0<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The March 2026 NHS England Board papers describe a system moving from broad recovery planning into a more demanding phase of delivery control.\u00a0 The overall signal is not one of simple improvement or deterioration. It is more complex. Elective waiting lists are reducing, some urgent and emergency care measures are improving, cancer early diagnosis is…<\/p>\n","protected":false},"author":26,"featured_media":63121,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","footnotes":""},"categories":[25],"tags":[],"class_list":["post-63118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-leadership"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/comments?post=63118"}],"version-history":[{"count":1,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63118\/revisions"}],"predecessor-version":[{"id":63122,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63118\/revisions\/63122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media\/63121"}],"wp:attachment":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media?parent=63118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/categories?post=63118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/tags?post=63118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}